Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.
IPO Year:
Exchange: NASDAQ
Website: bigcypressaccorp.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/4/2021 | $18.00 | Outperform | Northland Capital Markets |
| 10/1/2021 | $16.50 | Buy | Ladenburg Thalmann |
SC 13D - SAB Biotherapeutics, Inc. (0001833214) (Subject)
SC 13D - SAB Biotherapeutics, Inc. (0001833214) (Subject)
SC 13D - SAB Biotherapeutics, Inc. (0001833214) (Subject)
SC 13G - Big Cypress Acquisition Corp. (0001833214) (Subject)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
Northland Capital Markets initiated coverage of Big Cypress Acquisition with a rating of Outperform and set a new price target of $18.00
Ladenburg Thalmann initiated coverage of Big Cypress Acquisition with a rating of Buy and set a new price target of $16.50
8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)
25-NSE - Big Cypress Acquisition Corp. (0001833214) (Subject)
8-K - Big Cypress Acquisition Corp. (0001833214) (Filer)
425 - Big Cypress Acquisition Corp. (0001833214) (Subject)
8-K - Big Cypress Acquisition Corp. (0001833214) (Filer)
425 - Big Cypress Acquisition Corp. (0001833214) (Subject)
8-K - Big Cypress Acquisition Corp. (0001833214) (Filer)
425 - Big Cypress Acquisition Corp. (0001833214) (Subject)
425 - Big Cypress Acquisition Corp. (0001833214) (Subject)
425 - Big Cypress Acquisition Corp. (0001833214) (Subject)
Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol "SABS" SIOUX FALLS, S.D., Oct. 25, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the completion of its business combination with Big Cypress Acquisition Corp. (NASDAQ:BCYP) ("Big Cypress"), a publicly-traded special purpose acquisition company (SPAC) focused on innovative biopharmaceutical
MIAMI, Oct. 21, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ:BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that its stockholders have approved the proposed business combination (the "Business Combination") with SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease and immune system disorders, at a Special Meeting of stockholders held on October 20, 2021 (the "Special Meeting"). Approximately 98.3% of t
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it will host a virtual R&D Day on Wednesday, October 13, 2021, at 10:00 a.m. ET to showcase its versatile DiversitAb™ platform and pipeline of clinical and preclinical programs. The event will feature SAB management and key opinion leaders, including: Arturo Casadevall, MD, PhD – The Alfred and Jill Sommer Professor and Chair, W. Harry Feinstone Department of Molecular Microbiology & Immunology, Bloomberg Distinguished Professor, Johns Hopkins B
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced that the first patient has been dosed with SAB-185 in the Phase 3 ACTIV-2 COVID-19 trial. SAB-185 is a fully human, specifically targeted, broadly neutralizing polyclonal antibody therapeutic candidate for the treatment of non-hospitalized patients with mild to moderate COVID-19. The candidate is being assessed in the ACTIV-2 trial led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NI
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021. Mr. Beyer will lead all aspects of SAB's financial operations and key supporting functions and will work with the senior management team to drive SAB's growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005435/en/(Photo: Business Wire) "We welcome Russell to the SAB team at an exciting t
Advancement to Phase 3 is major milestone for SAB's unique DiversitAb™ immunotherapy platform that produces fully-human polyclonal antibodies without human donors Both doses of SAB-185 tested in Phase 2 met pre-defined efficacy goal at interim analysis SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its prespecified interim analysis data review of the safety and efficacy of SAB-185 in the Phase 2 portion of the ACTIV-2 trial and
MIAMI, Sept. 23, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp (NASDAQ:BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that it will hold a Special Meeting of stockholders (the "Special Meeting") to, among other matters, allow its stockholders to approve the proposed business combination (the "Business Combination") with SAB Biotherapeutics, Inc., (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease, immune system disorders and oncology. On
$200 million total awarded to date for DiversitAb™ Rapid Response Antibody Program including Stage 4 COVID-19 Pandemic Response Expanded contract scope includes commercial manufacturing and clinical development through licensure for SAB-185 for the treatment of COVID-19 SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that the U.S. Department of Defense (DoD) has awarded the company an additional $60.5 million in expanded scope for its DiversitAb™ Rapid Response Antibody Program for advanced clinica
Topline data expected in 4Q2021 SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the completion of enrollment in its Phase 2a clinical trial evaluating the safety and efficacy of SAB-176 in a challenge study. SAB-176 is a novel anti-influenza human immunotherapy designed to address the limitations of current treatments for moderate to severe seasonal influenza. It is a high-potency multivalent human polyclonal antibody therapeutic designed specifically to treat or prevent Type A and Type B seasonal a
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will present at two upcoming virtual investor conferences in September. Presentation details can be found below: H.C. Wainwright 23rd Annual Global Investment Conference. Format: Pre-recorded presentation available for on-demand viewing Date/Time: Monday, September 13 at 7:00 a.m. ET through Sunday, December 12 at 7:00 a.m. ET Registration Link Baird Global Healthcare Conference Format: Fi
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021. Mr. Beyer will lead all aspects of SAB's financial operations and key supporting functions and will work with the senior management team to drive SAB's growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005435/en/(Photo: Business Wire) "We welcome Russell to the SAB team at an exciting t